These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 7664458)

  • 1. Cost-effectiveness and diagnosis of coronary artery disease.
    Bryg RJ
    Circulation; 1995 Sep; 92(6):1669-70. PubMed ID: 7664458
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
    Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
    Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An educational tool to illustrate cost-effectiveness in diagnostic pathways for coronary artery disease.
    Jacklin PB; West PA; Sariklis D; Beech R; Maisey MN
    MD Comput; 2000; 17(1):49-57. PubMed ID: 10710936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of transradial coronary access.
    Kiemeneij F
    J Invasive Cardiol; 2007 Aug; 19(8):354. PubMed ID: 17712205
    [No Abstract]   [Full Text] [Related]  

  • 5. Left ventricular opacification for the diagnosis of coronary artery disease with stress echocardiography: an angiographic study of incremental benefit and cost-effectiveness.
    Moir S; Shaw L; Haluska B; Jenkins C; Marwick TH
    Am Heart J; 2007 Sep; 154(3):510-8. PubMed ID: 17719299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medical-economical aspects of high sensitivity C-reactive protein assay for the prediction of coronary heart disease. An analysis in Germany and Italy.
    Ess SM; Szucs TD
    Ital Heart J; 2001 Mar; 2(3):181-8. PubMed ID: 11305529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of coronary artery disease: is there a cost-effective way to do it?
    Stanford W
    Am J Card Imaging; 1996 Jul; 10(3):180-6. PubMed ID: 8914705
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved quality and cost-effectiveness of coronary artery bypass grafting in the United States from 1988 to 2005.
    Song HK; Diggs BS; Slater MS; Guyton SW; Ungerleider RM; Welke KF
    J Thorac Cardiovasc Surg; 2009 Jan; 137(1):65-9. PubMed ID: 19154905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis in diagnosis of coronary artery disease: choice of laboratory markers.
    Bogavac-Stanojević N; Ivanova Petrova G; Jelić-Ivanović Z; Memon L; Spasić S
    Clin Biochem; 2007 Nov; 40(16-17):1180-7. PubMed ID: 17869234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
    Rivière M; Wang S; Leclerc C; Fitzsimon C; Tretiak R
    CMAJ; 1997 Apr; 156(7):991-7. PubMed ID: 9099167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effect clinical analysis in choice of methods of coronary heart disease diagnosis].
    Kalashnikov VIu; Mitriagina SN; Syrkin AL; Poltavskaia MG
    Ter Arkh; 2008; 80(4):8-11. PubMed ID: 18491572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A comparative study of 4 diagnostic strategies in coronary artery disease. A theoretical approach].
    Henry P; Makowski S; Guermonprez JL; Guize L
    Arch Mal Coeur Vaiss; 1997 Mar; 90(3):327-35. PubMed ID: 9232070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic retinopathy and coronary artery disease from the cardiac surgeon's perspective.
    Ohno T; Takamoto S; Motomura N
    Ann Thorac Surg; 2008 Feb; 85(2):681-9. PubMed ID: 18222304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of cardiac rehabilitation program delivery models in patients at varying cardiac risk, reason for referral, and sex.
    Papadakis S; Reid RD; Coyle D; Beaton L; Angus D; Oldridge N
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):347-53. PubMed ID: 18525392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.